The Sudden Arrhythmia Death Syndromes (SADS) Foundation

The MDC trial included 343 patients (mean age 49 years) with nonischemic dilated cardiomyopathy, 94% who were in NYHA class II or III HF with a mean LVEF of 22%. Patients on immediate-release metoprolol tartrate experienced a significant improvement in LVEF, exercise capacity, and quality of life.17 Lower doses were used in these trials ... ................
................